WHC+ (Women's Health CoOp PLUS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01497405 |
Recruitment Status
:
Completed
First Posted
: December 22, 2011
Last Update Posted
: September 20, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Sexual Risk Sexually Transmitted Diseases Substance Abuse Violence Victimization | Behavioral: Test, Treat, Retain(TTR) + Women's Health CoOp (WHC) Biological: Test, Treat, Retain(TTR) only | Phase 1 |
There is growing recognition that no single strategy will be sufficient to eliminate transmission. In light of evidence that neither existing biomedical interventions nor any existing behavioral interventions will be sufficient to control the HIV epidemic in South Africa, the proposed study will combine a biomedical intervention with an evidence-based behavioral intervention (i.e., the Women's Health CoOp) to maximize the efficacy of both strategies. If this combination intervention proves efficacious, there is a high likelihood that it can be widely implemented, be sustainable and have a substantial public health impact by reducing the exceedingly high HIV incidence in South Africa.
The overarching goal of the proposed research is to determine whether this enhanced combination prevention strategy targeting vulnerable AOD-using women is more efficacious than current standard practices. The specific aims of the proposed study are:
Aim 1: To expand the WHC outreach strategies to reach more alcohol and other drug (AOD) - using vulnerable women in Pretoria, South Africa.
Aim 2: To test whether adding WHC to standard Treat, Test, and Retain (TTR) practices results in more HIV-positive AOD-using women getting medical evaluations (e.g., cluster of differentiation 4 (CD4), viral load), starting treatment, staying in treatment and in greater reductions in risk behaviors (e.g., AOD use, condom use, victimization) among all women-positive or negative.
The study uses a geographical cluster randomized design. Hotspots (i.e. places where sex workers and drug using women congregate) in the city of Pretoria and the surrounding areas were mapped using geographic information system (GIS) software. Fourteen hotspots were identified and geocoded. The entire area was divided into 14 zones, each of which included a hotspot. Seven matched pairs of zones were created based on socio-economic conditions and estimates of the numbers of sex workers and drug-using women residing in them. Zones within pairs were randomized to the TTR arm or the WHC+ arm. Participants are recruited by outreach workers and their intervention condition is based on the zone from which they were recruited. At study enrollment/baseline, eligible participants complete a questionnaire and baseline HIV, drug and pregnancy testing. Follow-up data collection will be conducted at 6-months and 12-months post-baseline.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 641 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Combination Prevention for Vulnerable Women in South Africa |
Study Start Date : | May 2012 |
Actual Primary Completion Date : | December 2015 |
Actual Study Completion Date : | December 2015 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Test, Treat, Retain(TTR) only
Participants in this group will be screened for HIV. HIV positive women will be given post-test counseling and referrals for prompt medical evaluation.
|
Biological: Test, Treat, Retain(TTR) only
TTR +only: Participants in this group will be screened for HIV. HIV positive women will be given post-test counseling and referrals for prompt medical evaluation.
|
Experimental: Test, Treat, Retain(TTR) + Women's Health CoOp (WHC)
TTR +WHC: Participants in this group will be screened for HIV. HIV positive women, will be given post-test counseling and referrals for prompt medical evaluation and assessment. Both HIV negative and positive participants in this group will participate in 2 individual behavioral counseling sessions focusing on reducing HIV risk behaviours, alcohol and other drug use, and risk of violent victimization. It also adds case management to increase follow through with referrals and risk reduction plans and activities. This intervention is an adaptation of the evidence-based Women's CoOp(PI: Dr. Wendee M. Wechsberg).
|
Behavioral: Test, Treat, Retain(TTR) + Women's Health CoOp (WHC)
TTR +WHC: Participants in this group will be screened for HIV. HIV positive women, will be given post-test counseling and referrals for prompt medical evaluation and assessment.Both HIV negative and positive participants in this group will participate in 2 individual behavioral counseling sessions focusing on reducing HIV risk behaviours, alcohol and other drug use, and risk of violent victimization. It also adds case management to increase follow through with referrals and risk reduction plans and activities.This will also include case management sessions. This intervention is an adaptation of the evidence-based Women's CoOp (PI: Dr. Wendee M. Wechsberg).
|
- Unprotected intercourse among women [ Time Frame: 6 months ]Percentages of condom use at last sex
- Unprotected intercourse among women [ Time Frame: 12 months ]Percentages of condom use at last sex
- Medical evaluation initiation amongst HIV-positive [ Time Frame: 6 months ]Percentages of HIV-positive women receiving medical evaluations.
- Medical evaluation initiation amongst HIV-positive [ Time Frame: 12 months ]Percentages of HIV-positive women receiving medical evaluations.
- Treatment initiation and retention amongst HIV-positive women [ Time Frame: 6 months ]Percentages of HIV-positive women starting and staying in treatment
- Treatment initiation and retention amongst HIV-positive women [ Time Frame: 12 months ]Percentages of HIV-positive women starting and staying in treatment
- HIV viral load among HIV-positive women who meet criteria for antiretroviral treatment (ART) and who produce medical records with HIV viral loads [ Time Frame: 6 months ]HIV viral load from medical record
- HIV viral load among HIV-positive women who meet criteria for antiretroviral treatment (ART) and who produce medical records with HIV viral loads [ Time Frame: 12 months ]HIV viral load from medical record
- Alcohol use [ Time Frame: 6 months post intervention ]Frequency of alcohol use in previous 30 days measured by Revised Risk Behavior Assessment (RRBA) and breath test
- Alcohol use [ Time Frame: 12 months post intervention ]Frequency of alcohol use in previous 30 days measured by Revised Risk Behavior Assessment (RRBA) and breath test
- Victimization [ Time Frame: 6 months post intervention ]Percentages of women who report being beaten, attacked with a weapon, or forced to have sex in the previous 90 days
- Victimization [ Time Frame: 12 months post intervention ]Percentages of women who report being beaten, attacked with a weapon, or forced to have sex in the previous 90 days

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 15 Years to 55 Years (Child, Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Female
- Black/African
- 15 years or older (if under 18, must be able to sign assent)
- Use at least one of the following drugs: alcohol, marijuana (dagga), methamphetamine (tik), Mandrax (methaqualone), cocaine (crack and/or powder), heroin (Thai White), inhalants (glue and benzene) methylenedioxymethamphetamine (MDMA -ecstasy), lysergic acid diethylamide (LSD), or Kat/cat, Nyaope (a mixture of marijuana and heroin) — weekly in the past 90 days
- Have had unprotected vaginal sex with a male partner in the last six months
- Able to speak English, Sesotho, Tswana, or Zulu
- Consent to HIV rapid testing and drug testing
- Provide written verbal and assent/consent to participate
- Able to provide verifiable locator information for the Tshwane area and plan to stay there in the next 12 months
Exclusion Criteria:
- Males
- Individuals who do not self-identify as Black/African

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01497405
United States, North Carolina | |
RTI International - Headquarters | |
Research Triangle Park, North Carolina, United States, 27709 | |
South Africa | |
Wesley Community Centre | |
Pretoria, South Africa, 0126 |
Principal Investigator: | Wendee M Wechsberg, PhD | RTI International |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | RTI International |
ClinicalTrials.gov Identifier: | NCT01497405 History of Changes |
Other Study ID Numbers: |
1R01DA032061-01 ( U.S. NIH Grant/Contract ) |
First Posted: | December 22, 2011 Key Record Dates |
Last Update Posted: | September 20, 2017 |
Last Verified: | September 2017 |
Keywords provided by RTI International:
Gender-based Violence HIV Randomized Controlled Trial |
Sexually Transmitted Diseases Substance Abuse Detection Test, Treat and Retain |
Additional relevant MeSH terms:
Substance-Related Disorders Sexually Transmitted Diseases Chemically-Induced Disorders Mental Disorders |
Infection Virus Diseases Genital Diseases, Male Genital Diseases, Female |